MOG Antibody Associated Disorders Treatment Market
Number of pages: 100 | Report Format: PDF | Published date: April 11, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
CAGR |
3.7% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Drug Class, Distribution Channel, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global MOG antibody associated disorders treatment market is expected to register a revenue CAGR of 3.7% during the forecast period from 2023 to 2031.
MOG Antibody Associated Disorders Treatment Market Fundamentals
The immunoglobulin (Ig) superfamily member myelin oligodendrocyte glycoprotein (MOG) is a myelin protein that is expressed at the outermost lamellae of myelin sheath and oligodendrocyte (OGD) membranes. In various neurological conditions, including multiple sclerosis (MS), neuromyelitis optica spectrum disorders (NMOSD), and acute disseminated encephalomyelitis, MOG is a target of autoantibodies. The MOG antibody associated disorders treatment is not entirely apparent and is mostly based on neuromyelitis optica spectrum disorders experience. Any prescription is made off-label because there are currently no approved medications for long-term prevention of recurrence in adult MOG antibody associated disorders patients. However, recent research has indicated that treating MOG antibody associated disorders patients with immunosuppressive drugs such as mycophenolate mofetil and rituximab has positive outcomes. The best action for treating this rare autoimmune illness will require further study. In clinical practice, the choice to begin long-term relapse prevention treatment depends on the likelihood of subsequent relapses, the opportunity for recovery, and the persistence of MOG-IgG over time. In this context, rituximab, human intravenous (IV) IgG, azathioprine (AZA), and mycophenolate mofetil are the most frequently utilized therapies for adult MOG antibody associated disorder patients.
MOG Antibody Associated Disorders Treatment Market Dynamics
The increased prevalence of the MOG antibody associated disorders is the most important factor supporting the MOG antibody associated disorders treatment market demand. According to research, the anti-MOG antibody is present in 40% and 58% of kids diagnosed with acute disseminated encephalomyelitis. Even though MOG antibody associated disorders, neuromyelitis optica spectrum disorders, and acute disseminated encephalomyelitis share many similarities, it seems that MOG antibody associated disorders are distinct immunological illnesses. The prevalence and importance of immune-mediated inflammatory disorders (IMIDs) are rising in contemporary society, significantly affecting the patient and the healthcare system. Increased emergence of these diseases triggers the development of MOG antibody associated disorders. Therefore, advanced therapeutics, robust pipeline drugs, and novel treatment strategies are the current opportunities for the MOG antibody associated disorders treatment market. Therefore, MOG antibody associated disorders treatment market trends are urgently needed to address the growing burden of MOG antibody related disorders and improve patient outcomes. Additionally, further research is necessary to understand these diseases’ underlying mechanisms better and identify potential intervention targets.
Myelin oligodendrocyte glycoprotein (MOG) antibodies have recently attracted the attention of researchers, particularly in pediatric acute demyelinating syndromes (ADS), where these antibodies are frequently observed. With adult cohorts having a higher percentage of optic neuritis (ON) involvement and pediatric generations having acute disseminated encephalomyelitis, there appears to be an age-related component connected with the onset phenotype. In some areas, MOG antibody associated disorders are probably at least twice as common as neuromyelitis optica spectrum disorders. These results imply that age may be a factor in the development of MOG antibody associated disorders and that the disease may present differently depending on the age group. Thus, the increasing population is also one of the main factors contributing to the exponential revenue growth in the MOG antibody associated disorders treatment market. As the demand for MOG antibody associated disorders treatment rises with the increasing population, there is a need for innovative and cost-effective solutions to cater to the growing market. Developing advanced technologies and therapies can help meet this demand and provide better healthcare outcomes.
However, steroids are most frequently administered as a first-line treatment for MOG antibody associated disorders treatment. These steroids have multiple side effects which restrict the revenue growth of the MOG antibody associated disorders treatment market.
MOG Antibody Associated Disorders Treatment Market Ecosystem
This report provides the global MOG antibody associated disorders treatment market analysis in terms of revenue, market growth, market dynamics, regional landscape, and overall competitive positioning of the major market players. The global MOG antibody associated disorders treatment market is analyzed from three perspectives: drug class, distribution channel, and region.
MOG Antibody Associated Disorders Treatment Market by Drug Class
[1254]
Based on the drug class, the global MOG antibody associated disorders treatment market is segmented as corticosteroids, immunosuppressants, intravenous immunoglobulin, and others.
Intravenous immunoglobulin segment is frequently used for the treatment of MOG antibody associated disorders. Corticosteroids are the most effective treatment for reducing primary symptoms and preventing disease progression. The easy availability of corticosteroids is also a crucial factor for driving the segment’s revenue growth. Corticosteroids rapidly decrease inflammation associated with MOG antibody associated disorders, for which it is frequently prescribed therapeutics for MOG antibody associated disorders.
Moreover, immunosuppressants, such as mycophenolate mofetil, rituximab, and azathioprine, are the main treatments utilized in the United States. The drug with the longest history of use for illnesses linked to MOG antibodies is azathioprine. Recent research has revealed that additional immunosuppressive treatments, like rituximab and mycophenolate mofetil, have also proved successful in treating these conditions. The optimum course of treatment for each patient should be decided in close consultation with their healthcare professional.
Intravenous immunoglobulin maintenance (IVIG) may be an effective treatment for preventing relapse in MOG antibody associated disorders. Future market revenue growth is expected to be aided by the rising use of immunoglobulin due to new product introductions and regulatory approvals. Accessibility and cost-effectiveness may also impact how frequently intravenous immunoglobulin is used as a therapeutic option.
MOG Antibody Associated Disorders Treatment Market by Distribution Channel
Based on the distribution channel, the global MOG antibody associated disorders treatment market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
The hospital pharmacies segment accounts for the largest revenue share of the global MOG Antibody Associated Disorders Treatment market in 2022. Since MOG antibody-associated disorders are rare diseases, specialist knowledge and skill are needed to diagnose and treat this condition. As hospital pharmacies may have access to the most recent research and treatments, MOG antibody associated disorders patients may benefit from receiving care at a hospital with a specialist clinical staff with experience treating this illness. Hospital pharmacies frequently offer access to specialist drugs unavailable in retail pharmacies and a greater selection of prescriptions. Clinical pharmacists in hospital teams caring for MOG antibody associated disorders patients can also educate patients and their families on medication use, keep an eye out for possible drug interactions and side effects, and modify medication schedules as necessary based on patient response. Immunosuppressive medications, which are often only accessible in hospital settings, are frequently necessary for the treatment of MOG antibody associated disorders. However, MOG antibody associated disorders patients can get these immunosuppressant medications in an outpatient setting with careful medication administration and monitoring. This may result in more comfortable patient care and lower medical expenses. Hospital pharmacies frequently have stronger connections with pharmaceutical companies and can bargain lower pricing for specialty medications, making them more affordable for patients with MOG antibody associated disorders. Due to their competence, and access to particular medicines, hospital pharmacy leads the market for MOG antibody associated disorders treatments market revenue.
MOG Antibody Associated Disorders Treatment Market by Region
Based on the region, the global MOG antibody associated disorders treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America accounted for the largest revenue share of the global MOG antibody associated disorders treatment market in 2022. The streamlined repayment laws in North America and an increase in the occurrence of MOG antibody associated disorders are expected to assist the revenue growth of the MOG antibody associated disorders treatment market in North America. The region’s market for advanced healthcare services is reportedly driven by several factors, including a well-established healthcare infrastructure, industry heavyweights, recently released cutting-edge instruments, payment coverage, and more. The growing population’s knowledge of modern healthcare services and rising disposable income are also expected to contribute to North America’s revenue growth. The market revenue is expanding significantly as more people become aware of rare diseases such as MOG antibody associated disorders, their treatments, and the related preventive measures. As a result, there is an increasing need for institutions and healthcare professionals with specialized training to handle the unique needs of patients with rare diseases. Healthcare providers can now participate in research and development to offer cutting-edge therapies. This pattern is especially noticeable in intravenous immunoglobulin treatment, where the demand for specialized healthcare workers and facilities to provide these cutting-edge therapies successfully is rising. Accordingly, healthcare professionals may enhance patient outcomes while advancing science and technology in the medical field.
Competitive Landscape of the Global MOG Antibody Associated Disorders Treatment Market
The potent drug pipeline is giving this market a big boost. The pharmaceutical industry is spending a lot on research and development to create new medications to meet the rising demand. Market participants are implementing various methods to increase their market penetration and share, including distribution, mergers and acquisitions, and other cooperative arrangements. Different industry companies are also being influenced to invest due to the increased prevalence of MOG antibody-associated illnesses and the rising demand for cutting-edge treatments. During the forecast period, innovative therapeutics and customized medicine are expected to accelerate market revenue growth. Notable market participants operating in the global MOG antibody associated disorders treatment market with the largest revenue share are:
Strategic Development in the MOG Antibody Associated Disorders Treatment Market
The immunoglobulin (Ig) superfamily member myelin oligodendrocyte glycoprotein (MOG) is a myelin protein that is expressed at the outermost lamellae of myelin sheath and oligodendrocyte (OGD) membranes. In various neurological conditions, including multiple sclerosis (MS), neuromyelitis optica spectrum disorders (NMOSD), and acute disseminated encephalomyelitis, MOG is a target of autoantibodies.
The increased prevalence of MOG antibody associated disorders and increased awareness are the key factors driving the revenue growth of the global MOG antibody associated disorders treatment market.
The high cost and complications are restraining the revenue growth of the global MOG antibody associated disorders treatment market.
Key companies operating the global MOG antibody associated disorders treatment market are Merck & Co., Inc., GlaxoSmithKline Pharmaceuticals Ltd., Novartis AG, Pfizer Inc., Biotest AG, Baxter International Inc., and Octapharma AG.
The global MOG antibody associated disorders treatment market is expected to grow at a revenue CAGR of 3.7% during the forecast period from 2023 to 2031.
*Insights on financial performance are subject to the availability of information in the public domain